Delisted
Stopped trading. Fund positions aren't valued until we confirm what happened.
DBTX (Decibel Therapeutics Inc) is held by 0 institutional investors as of Q3 2023.
0
Holders
$0
Total Value
0%
Consensus
13F: Insider & Congress: Updated regularly
No verdict yet — fewer than 2 funds hold DBTX.
Top Holders
Checking access…
| Action | ||||||
|---|---|---|---|---|---|---|
Exited | 0(-100.0%) | $6.3M | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $41,792 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $3,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $133,237 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $226,380 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $155,883 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $362 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $73,500 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $39 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $6,680 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $15,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $132,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $77,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $157,696 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $57,365 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $508,200 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $444,932 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $613,012 | 0.0% | — | 0 |
DBTXDecibel Therapeutics IncContinue exploring
Similar stocks
FISVFISERV INC336 holders · $21.1B
SPYSTATE STR SPDR S&P 500 ETF T296 holders · $348.5B
IVVISHARES TR263 holders · $566.9B
QQQINVESCO QQQ TR246 holders · $125.8B
VOOVANGUARD INDEX FDS246 holders · $265B
IWMISHARES TR242 holders · $68.1B
GLDSPDR GOLD TR238 holders · $33.2B
XLFSELECT SECTOR SPDR TR225 holders · $31.5B
XLESELECT SECTOR SPDR TR223 holders · $17.3B
EFAISHARES TR221 holders · $47.1B
Questions investors ask about DBTX
Who owns DBTX?
0 institutional investors held DBTX on September 30, 2023, according to their 13F filings.
How many hedge funds hold DBTX?
0 institutional investors reported DBTX in their 13F filings for the quarter ended September 30, 2023.
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer